WallStSmart

Alcon AG (ALC)vsDaxor Corporation (DXR)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Alcon AG generates 34633191% more annual revenue ($10.86B vs $31,360). DXR leads profitability with a 19861.0% profit margin vs 5.9%. DXR trades at a lower P/E of 8.9x. ALC earns a higher WallStSmart Score of 51/100 (C-).

ALC

Buy

51

out of 100

Grade: C-

Growth: 4.7Profit: 4.5Value: 3.3Quality: 7.3
Piotroski: 4/9

DXR

Hold

49

out of 100

Grade: D+

Growth: 6.7Profit: 5.5Value: 6.7Quality: 4.8
Piotroski: 2/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-23.1%)

Margin of Safety

-23.1%

Fair Value

$64.49

Current Price

$69.83

$5.34 premium

UndervaluedFair: $64.49Overvalued

Intrinsic value data unavailable for DXR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

DXR6 strengths · Avg: 9.5/10
P/E RatioValuation
8.9x10/10

Attractively priced relative to earnings

Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Profit MarginProfitability
19861.0%10/10

Keeps 19861 of every $100 in revenue as profit

EPS GrowthGrowth
329.3%10/10

Earnings expanding 329.3% YoY

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Revenue GrowthGrowth
25.5%8/10

Revenue surging 25.5% year-over-year

Areas to Watch

ALC4 concerns · Avg: 2.5/10
Return on EquityProfitability
3.0%3/10

ROE of 3.0% — below average capital efficiency

Profit MarginProfitability
5.9%3/10

5.9% margin — thin

P/E RatioValuation
53.2x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-44.6%2/10

Earnings declined 44.6%

DXR4 concerns · Avg: 2.3/10
Market CapQuality
$56.92M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Free Cash FlowQuality
$-2.51M2/10

Negative free cash flow — burning cash

Operating MarginProfitability
-4530.0%1/10

Operating margin of -4530.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book. PEG of 1.21 suggests the stock is reasonably priced for its growth.

Bull Case : DXR

The strongest argument for DXR centers on P/E Ratio, Price/Book, Profit Margin. Profitability is solid with margins at 19861.0% and operating margin at -4530.0%. Revenue growth of 25.5% demonstrates continued momentum.

Bear Case : ALC

The primary concerns for ALC are Return on Equity, Profit Margin, P/E Ratio. A P/E of 53.2x leaves little room for execution misses.

Bear Case : DXR

The primary concerns for DXR are Market Cap, Piotroski F-Score, Free Cash Flow.

Key Dynamics to Monitor

ALC profiles as a value stock while DXR is a growth play — different risk/reward profiles.

ALC carries more volatility with a beta of 0.73 — expect wider price swings.

DXR is growing revenue faster at 25.5% — sustainability is the question.

ALC generates stronger free cash flow (414M), providing more financial flexibility.

Bottom Line

ALC scores higher overall (51/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Daxor Corporation

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Daxor Corporation, a medical device company, provides cryobank and biotechnology services in the United States. The company is headquartered in New York, New York.

Want to dig deeper into these stocks?